Skip to content

Platform
- Overview
- Publications
Pipeline
Patients
About Us
Partnerships
News
Careers

Platform
- Overview
- Publications
Pipeline
Patients
About Us
Partnerships
News
Careers

COUR Pharmaceuticals Announces $30M Financing Led by Alpha Wave Ventures

By lsc-webmaster / September 7, 2022

COUR NanoParticle (CNP) Technology Induces Antigen Specific Tolerance, Halting the Progression of Type 1 Diabetes in Spontaneous NOD Model

COUR Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Myasthenia Gravis

Skokie, Illinois
info@courpharma.com

Science

Platform
Publications
Pipeline

Patients

Overview
Patient Resources
CNP-103 Clinical Trial in Type 1 Diabetes
CNP-106 Clinical Trial in Myasthenia Gravis

Company

About Us
Partnerships
News
Careers

Privacy Policy
Terms of use
Accessibility
Expanded Access Policy
Cookie policy

© 2025 COUR Pharmaceuticals

Scroll to Top